Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
2309 | 4089 | 30.3 | 67% |
Classes in level above (level 3) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
178 | 53417 | HEMOGLOBIN//SICKLE CELL DISEASE//IRON OVERLOAD |
Classes in level below (level 1) |
ID, lev. below | Publications | Label for level below |
---|---|---|
1181 | 2701 | DEFERASIROX//IRON OVERLOAD//DEFERIPRONE |
13767 | 752 | THALASSEMIA MAJOR//MOL DIAGNOST BIOPHARMACEUT//BETA THALASSEMIA MAJOR |
22918 | 308 | CONGENITAL DYSERYTHROPOIETIC ANEMIA//CONGENITAL DYSERYTHROPOIETIC ANAEMIA//HEMPAS |
26586 | 205 | AHSP//ALPHA HEMOGLOBIN STABILIZING PROTEIN AHSP//ALPHA HEMOGLOBIN STABILIZING PROTEIN |
31404 | 123 | DEV MODEL//PROTEIN WORD//DEV |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | IRON OVERLOAD | Author keyword | 247 | 36% | 13% | 551 |
2 | THALASSEMIA | Author keyword | 232 | 35% | 13% | 544 |
3 | DEFERASIROX | Author keyword | 225 | 73% | 4% | 174 |
4 | THALASSEMIA MAJOR | Author keyword | 155 | 63% | 4% | 157 |
5 | DEFERIPRONE | Author keyword | 127 | 58% | 4% | 147 |
6 | IRON CHELATION THERAPY | Author keyword | 99 | 78% | 2% | 65 |
7 | MICROCITEMIA | Address | 73 | 96% | 1% | 23 |
8 | THALASSAEMIA | Author keyword | 60 | 36% | 3% | 135 |
9 | BETA THALASSEMIA MAJOR | Author keyword | 60 | 54% | 2% | 77 |
10 | DEFERIPRONE L1 | Author keyword | 51 | 79% | 1% | 33 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | IRON OVERLOAD | 247 | 36% | 13% | 551 | Search IRON+OVERLOAD | Search IRON+OVERLOAD |
2 | THALASSEMIA | 232 | 35% | 13% | 544 | Search THALASSEMIA | Search THALASSEMIA |
3 | DEFERASIROX | 225 | 73% | 4% | 174 | Search DEFERASIROX | Search DEFERASIROX |
4 | THALASSEMIA MAJOR | 155 | 63% | 4% | 157 | Search THALASSEMIA+MAJOR | Search THALASSEMIA+MAJOR |
5 | DEFERIPRONE | 127 | 58% | 4% | 147 | Search DEFERIPRONE | Search DEFERIPRONE |
6 | IRON CHELATION THERAPY | 99 | 78% | 2% | 65 | Search IRON+CHELATION+THERAPY | Search IRON+CHELATION+THERAPY |
7 | THALASSAEMIA | 60 | 36% | 3% | 135 | Search THALASSAEMIA | Search THALASSAEMIA |
8 | BETA THALASSEMIA MAJOR | 60 | 54% | 2% | 77 | Search BETA+THALASSEMIA+MAJOR | Search BETA+THALASSEMIA+MAJOR |
9 | DEFERIPRONE L1 | 51 | 79% | 1% | 33 | Search DEFERIPRONE+L1 | Search DEFERIPRONE+L1 |
10 | IRON CHELATION | 49 | 33% | 3% | 123 | Search IRON+CHELATION | Search IRON+CHELATION |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MYOCARDIAL IRON | 478 | 90% | 5% | 205 |
2 | BETA THALASSEMIA | 297 | 31% | 20% | 803 |
3 | DEFEROXAMINE | 257 | 44% | 11% | 449 |
4 | THALASSEMIA MAJOR | 241 | 51% | 8% | 335 |
5 | ICL670 | 219 | 83% | 3% | 123 |
6 | DEFERIPRONE | 192 | 61% | 5% | 204 |
7 | CHELATION THERAPY | 167 | 50% | 6% | 242 |
8 | CARDIAC IRON | 147 | 85% | 2% | 78 |
9 | T2 ASTERISK CARDIOVASCULAR MAGNETIC RESONANCE | 140 | 92% | 1% | 56 |
10 | BETA THALASSEMIA MAJOR | 135 | 53% | 4% | 178 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Accuracy of Magnetic Resonance Imaging in Diagnosis of Liver Iron Overload: A Systematic Review and Meta-analysis | 2015 | 2 | 39 | 74% |
Iron-chelating therapy and the treatment of thalassemia | 1997 | 562 | 184 | 78% |
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms | 2015 | 1 | 32 | 78% |
Labile iron in cells and body fluids: physiology, pathology, and pharmacology | 2014 | 11 | 57 | 47% |
Non-transferrin bound iron: A key role in iron overload and iron toxicity | 2012 | 83 | 114 | 33% |
Beta-thalassemia | 2010 | 79 | 73 | 62% |
Results of long-perm iron-chelating therapy | 1996 | 196 | 59 | 85% |
Non-transfusion-dependent thalassemias | 2013 | 22 | 92 | 46% |
Bone disease and skeletal complications in patients with beta thalassemia major | 2011 | 27 | 89 | 94% |
Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major | 2014 | 3 | 22 | 100% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MICROCITEMIA | 73 | 96% | 0.6% | 23 |
2 | THALASSAEMIA UNIT | 39 | 64% | 0.9% | 38 |
3 | THALASSEMIA | 28 | 29% | 2.0% | 82 |
4 | CA GRANDA FDN IRCCS | 26 | 87% | 0.3% | 13 |
5 | THALASSEMIA UNIT | 21 | 44% | 0.9% | 37 |
6 | ANEMIE CONGENITE | 18 | 61% | 0.5% | 19 |
7 | MICROCITEMIE | 15 | 62% | 0.4% | 16 |
8 | CURA MICROCITEMIE | 14 | 100% | 0.2% | 7 |
9 | IRCCS CA GRANDA FDN MAGGIORE POLICLIN HOSP | 13 | 67% | 0.3% | 12 |
10 | UOS TALASSEMIA | 11 | 100% | 0.1% | 6 |
Related classes at same level (level 2) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000025186 | HEPCIDIN//HEMOCHROMATOSIS//IRON DEFICIENCY |
2 | 0.0000024727 | HEMOGLOBIN//SICKLE CELL DISEASE//SICKLE CELL ANEMIA |
3 | 0.0000013830 | SIDEROPHORE//SIDEROPHORES//PYOVERDINS |
4 | 0.0000007312 | PSEUDOXANTHOMA ELASTICUM//ABCC6//ANGIOID STREAKS |
5 | 0.0000005366 | G6PD DEFICIENCY//GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY//GLUCOSE 6 PHOSPHATE DEHYDROGENASE |
6 | 0.0000004969 | MAGNETOTACTIC BACTERIA//MAGNETORECEPTION//MAGNETOSOME |
7 | 0.0000004819 | BONE MARROW TRANSPLANTATION//GRAFT VERSUS HOST DISEASE//BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION |
8 | 0.0000004744 | ELECTROCHEMOTHERAPY//ELECTROPERMEABILIZATION//ELECTROPORATION |
9 | 0.0000004732 | MORINGA OLEIFERA//AL 13//POLYALUMINUM CHLORIDE |
10 | 0.0000004634 | ESSENTIAL THROMBOCYTHEMIA//POLYCYTHEMIA VERA//MYELOFIBROSIS |